An upcoming section on hcvguidelines.org, a website developed by IDSA and AASLD in collaboration with IAS-USA will examine the cost-effectiveness of HCV treatment to help clinicians advise and educate their patients, which is the purpose of the guidance. The new section will not, however, make recommendations regarding the pricing of these therapies for the treatment of HCV.
The Infectious Diseases Society of America (IDSA), in partnership with the ABIM Foundation’s Choosing Wisely campaign, has released a list of five tests or treatments that physicians and patients should question.
We urge parents to ensure that their children are up to date with all recommended immunizations, including with the MMR vaccine, to prevent this devastating disease from causing severe disability and death.
IDSA strongly supports the
proposal in the President’s Budget Request for Fiscal Year 2016.